Gritstone Oncology Inc. Stock News

EMERYVILLE, Calif., March 30, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immu

Wells Fargo raised the price target on Laredo Petroleum, Inc. (NYSE: LPI) from $72 to $113. Laredo Petroleum shares fell 2.8% to $71.00 in pre-market trading. HC Wainwright & Co. lowered Gritstone

Gritstone bio (GRTS) has filed for a $250M mixed shelf offering.

Gritstone bio Inc. (GRTS) delivered earnings and revenue surprises of 16.28% and 2.13%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Gritstone Oncology press release (NASDAQ:GRTS): Q4 GAAP EPS of -$0.95.Revenue of $48.21M.

-- Four trials now initiated for CORAL, Gritstone’s second-generation COVID-19 program focused on delivering T cell enhanced self-amplifying mRNA (samRNA) vaccines -- -- Oncology programs advancing as planned, with individualized neoantigen-based immunotherapy, GRANITE, now in a Phase 2/3 trial in newly diagnosed metastatic, microsatellite-stable colorectal cancer (MSS-CRC) patients and a Phase 2 trial of mutant KRAS-focused “off the shelf” neoantigen-based immunotherapy SLATE ongoing --

Gritstone bio Inc. (GRTS) delivered earnings and revenue surprises of 16.28% and 2.13%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Given that developing biotechnology companies are more susceptible to swings in stock price than established ones, investors might want to keep an eye on happenings at next month's American Associatio

-- Oral presentation to discuss how translational immunology data enabled iterative development of an optimized, KRAS-specific version of “off-the shelf” vaccine candidate; the optimized version i

EMERYVILLE, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immun

These unloved biotechs have enormous upside potential.

EMERYVILLE, Calif., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immun

Gritstone bio (GRTS) has an interesting platform and decent early-stage data in the Covid-19 indication. GRTS is also progressing the rest of its oncology pipeline through the clinic.

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Says Lead Monoclonal Antibody Effective Against Omicron Variant Adagio Therapeutics, Inc. (NASD